The Food and Drug Administration (FDA) is issuing a Request for Quote (RFQ) No. 75F40125Q00352 for two complete benchtop bioreactor systems. These systems will be used by the Office of Pharmaceutical Quality Research (OPQR) to cultivate Escherichia coli and investigate the impact of cell extract preparation on human therapeutic protein quality during cell-free protein synthesis (CFPS). The bioreactor systems must be capable of automated control and monitoring of temperature, pH, dissolved oxygen, foam levels, and turbidity, with a 10 L working volume for high-density E. coli culture. The solicitation is a small business set-aside, and quotes are due by 2:00 PM Eastern Time on August 21, 2025, via email to Janice.Heard@fda.hhs.gov. The contract will be a firm fixed-price purchase order, with delivery and installation required at the FDA White Oak Campus in Silver Spring, MD. The document outlines detailed technical specifications, required accessories, and various Federal Acquisition Regulation (FAR) and HHS Acquisition Regulation (HHSAR) clauses pertaining to commercial items, payment, and accessibility.